Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Crit Rev Oncol Hematol. 2010 Oct;76(1):13-35. doi: 10.1016/j.critrevonc.2009.12.004. Epub 2010 Aug 11.

Antiangiogenic strategies in breast cancer management.

Author information

  • 1Medical Oncology Unit, Oncology Dept, San Raffaele Scientific Institute-University Hospital, Milan, Italy. giovannini.monica@hsr.it

Abstract

Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.

Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

PMID:
20702105
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk